Multimodal therapy in aggressive pituitary tumors

Area of Science:

• Endocrinology
• Oncology
• Pathology

Background:

• Aggressive pituitary tumors (APTs) are increasingly recognized, distinct from typical adenomas and carcinomas.
• Characterized by invasion, high proliferative activity, and resistance to standard therapies, APTs account for approximately 10% of pituitary neoplasms.
• Distinguishing APTs from pituitary carcinomas relies on the absence of distant metastases.

Purpose of the Study:

• To define the diagnostic criteria for aggressive pituitary tumors.
• To outline the current therapeutic strategies and challenges in managing APTs.
• To highlight the unmet research needs in understanding and treating APTs.

Main Methods:

• Diagnosis involves radiological, hormonal, and detailed pathological assessment, including proliferation markers and immunohistochemistry.
• Initial management typically includes surgical resection (gross total or debulking).
• Treatment often requires multimodal approaches, including repeat surgeries, radiation, and various medical therapies.

Main Results:

• APTs exhibit invasive growth and high proliferative activity, leading to frequent recurrences and treatment resistance.
• Patients often require multiple interventions, including surgery, radiation, and advanced medical treatments like temozolomide, targeted therapies, or radionuclide therapy.
• Multimodal therapy, delivered by experts in high-volume centers, is crucial for improving patient prognosis.

Conclusions:

• Aggressive pituitary tumors necessitate a comprehensive diagnostic approach and aggressive multimodal treatment strategies.
• Specialized centers and expert management are vital for optimizing outcomes in patients with these challenging neoplasms.
• Further research into molecular biology, treatment protocols, and collaborative studies is essential for advancing APT care.